GenScript Biotech

San Francisco Witnesses the Voice of GCT Titans GenScript Biotech Global Forum Outlines the Future of the Industry

Retrieved on: 
Friday, January 12, 2024
Stanford University, DSM-IV codes, Overalls, Gene therapy, Flagship Pioneering, Biotechnology, Artificial intelligence, Neogene, CBER, Gene editing, Genome editing, Assistant professor, Therapy, Biological engineering, SAN, Humour, Harvard University, GenScript Biotech, Optimism, Safety, Patient, J. P. Morgan, AstraZeneca, Hope, GCT, Broad Institute, CBO, Process, Animal, Gene, ARCH Venture Partners, Multiple myeloma, Speech, Intellia Therapeutics, Development, Associate, Health, CRISPR, Intelligence, Courage, Research and development, Division, Conference, T cell, FDA, Eli Lilly and Company, SVP, Pharmaceutical industry

On January 10 this year, GenScript Biotech hosted the "Satellite Session" of the J.P. Morgan annual conference—the 2024 GenScript Biotech Global Forum in San Francisco.

Key Points: 
  • On January 10 this year, GenScript Biotech hosted the "Satellite Session" of the J.P. Morgan annual conference—the 2024 GenScript Biotech Global Forum in San Francisco.
  • GenScript Biotech is committed to building a high-quality platform for exchange and cooperation for global peers, driving the advancement of the cell and gene industry.
  • since the first global forum was held in 2020, GenScript Biotech has created numerous valuable opportunities for industry peers.
  • This grand event brought together the wisdom and strength of global elites in the biopharmaceutical industry, sparking a profound discourse on the future of GCT.

Enhancing Treatments using Targeted Protein Degradation, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Monday, December 18, 2023
Drug discovery, UPD, Protein, Cancer, Agriculture, Autoimmunity, GenScript Biotech, TPD, POI, Proteostasis, Vaccine, Fine chemical, Biochemistry

TORONTO, Dec. 18, 2023 /PRNewswire-PRWeb/ -- Discover a webinar delving into targeted protein degradation (TPD), an approach using cellular machinery to selectively remove proteins, promising more effective treatments with minimized side effects. The main classical small molecule drug discovery strategies are inhibiting the biological function of proteins of interest, which either block the active pocket or change the protein conformation. However, the significant disadvantages such as limitations in target candidates, dose issues and quick resistance foundations, are calling for a more preferable therapy with fewer side effects.

Key Points: 
  • In this free webinar, explore insights into targeted protein degradation (TPD) and learn new avenues for enhanced treatment efficacy through selective protein removal.
  • TORONTO, Dec. 18, 2023 /PRNewswire-PRWeb/ -- Discover a webinar delving into targeted protein degradation (TPD), an approach using cellular machinery to selectively remove proteins, promising more effective treatments with minimized side effects.
  • Join this webinar to explore insights into TPD and learn new avenues for enhanced treatment efficacy through selective protein removal.
  • Join Yongheng Huang, Doctor in Biochemistry, Protein Senior Scientist, GenScript , for the live webinar on Thursday, January 11, 2024, at 9am EST (3pm CET/EU-Central).

GenScript ProBio Signs Viral Vector Manufacturing MOU With Curocell for Next-Generation CAR-T Therapy

Retrieved on: 
Friday, November 10, 2023
Research, General Health, Pharmaceutical, Oncology, Hospitals, Genetics, Clinical Trials, Science, Cardiology, Biotechnology, Stem Cells, Health, Other Science, Antigen, GMP, Gene, CDMO, IND, GenScript Biotech, Virus, Cancer, Partnership, Growth, Immunotherapy, CGT, MOU, Vaccine, Hong Kong

On November 10, a global multimodality CDMO, GenScript ProBio and specialized CAR-T therapy firm Curocell signed a strategic partnership MOU for the production of viral vectors necessary for the development of next generation of CAR-T therapy, marking another significant step in their ongoing collaboration.

Key Points: 
  • On November 10, a global multimodality CDMO, GenScript ProBio and specialized CAR-T therapy firm Curocell signed a strategic partnership MOU for the production of viral vectors necessary for the development of next generation of CAR-T therapy, marking another significant step in their ongoing collaboration.
  • Viral vectors are vehicles for drug delivery that utilize viruses to transport genetic material to the cellular interior.
  • The demand for viral vectors is rapidly increasing due to the recent growth of the gene therapy market, which uses CAR-T therapy as its main active ingredient.
  • However, it has been noted that a shortage of GMP facilities producing viral vectors is causing delays in the development of gene therapies, including CAR-T therapy.

Titans Gather, Future Embarks: The GenScript Biotech Global Forum coinciding with the 2024 J.P. Morgan Healthcare Conference in San Francisco to Convene 20+ KOLs, Exploring Disruptive Transformations and Infinite Opportunities in GCT

Retrieved on: 
Thursday, December 14, 2023
Drug development, Eli Lilly and Company, Assistant, CBO, Partner (business rank), Senior, GenScript Biotech, Intellia Therapeutics, Gene editing, Entrepreneurship, Therapy, ARCH Venture Partners, Neogene, Biopharmaceutical, Flagship Pioneering, CSO, Value of life, FDA, Science, GCT, Forum, CRISPR, Speech, Life, Process, Medical device, Pharmaceutical industry, Nightclub, Fine chemical, Research

NANJING, China, Dec. 14, 2023 /PRNewswire/ -- Technological advancements continuously empower the life sciences. Gene and cell therapy (GCT), as breakthrough treatments, are turning the once-unreachable dream of curing many diseases into reality. Recently, the world's first CRISPR-Cas9 gene-editing therapy received market approval, marking another significant milestone in human biomedical progress.

Key Points: 
  • Gene and cell therapy (GCT), as breakthrough treatments, are turning the once-unreachable dream of curing many diseases into reality.
  • On January 10, 2024, the GenScript Biotech Global Forum will once again kick off in San Francisco.
  • Peter Marks, director of FDA's Center for Biologics Evaluation and Research (CBER) will make his keynote speech at the GenScript Biotech Global Forum.
  • On January 10, 2024, we cordially invite you to join us in San Francisco for the GenScript Biotech Global Forum.

GenScript to Host Biotech Global Forum 2024 during 42nd Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Thursday, December 14, 2023
Medicine, Research, Gene, GenScript Biotech, Patient, Cell, GCT, What Lies Ahead, Pharmaceutical industry, Conference

PISCATAWAY, N.J., Dec. 14, 2023 /PRNewswire/ -- GenScript Biotech Corporation, the world's leading provider of life-science research tools and services, is kicking off 2024 with the GenScript Biotech Global Forum 2024, concurrent with the 42nd Annual J.P. Morgan Healthcare Conference.

Key Points: 
  • Conference to convene gene- and cell-therapy thought leaders from the research, industry, and capital communities as well as representatives from regulatory bodies
    PISCATAWAY, N.J., Dec. 14, 2023 /PRNewswire/ -- GenScript Biotech Corporation , the world's leading provider of life-science research tools and services, is kicking off 2024 with the GenScript Biotech Global Forum 2024 , concurrent with the 42nd Annual J.P. Morgan Healthcare Conference.
  • As we close out 2023, the gene- and cell-therapy sector is booming worldwide, fueled by major innovations in life science and medicine and funding from global capital markets.
  • To advance this crucial field in 2024, GenScript is convening top scientists and industry leaders from around the world at the Grand Hyatt in San Francisco on Wednesday, January 10, 2024.
  • By providing a forum for thought leaders from around the world, the conference aims to accelerate the pursuit of cures that will help more patients.

GenScript Named a BioSpace 2024 Best Place to Work

Retrieved on: 
Friday, December 1, 2023
Work, Acceleration, Biotechnology, Research, GenScript Biotech, The Last Best Place, Culture, Management

PISCATAWAY, N.J., Dec. 1, 2023 /PRNewswire/ -- GenScript Biotech Corporation, the world's leading provider of life-science research tools and services, has been named among the Top 30 Large Employers as a BioSpace 2024 Best Place to Work. The list, now in its third year, includes 60 U.S. operating employers that have been recognized as the most sought-after in the industry by the life-sciences community.

Key Points: 
  • PISCATAWAY, N.J., Dec. 1, 2023 /PRNewswire/ -- GenScript Biotech Corporation , the world's leading provider of life-science research tools and services, has been named among the Top 30 Large Employers as a BioSpace 2024 Best Place to Work .
  • In compiling the list, BioSpace considers each organization's merits, with particular emphasis on culture, career growth and development opportunities, leadership, and innovation.
  • The 2024 "Best Places to Work" list highlights top life-sciences organizations that are doing the best they can to remain competitive, demonstrate core values, engage and retain employees, and attract top talent.
  • "We are immensely proud to be included in the large employer category of the BioSpace 2024 Best Places to Work.

Bispecific Antibodies: Structural Design, Production and Purification Strategies, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Wednesday, November 22, 2023
Bispecific monoclonal antibody, Research, Antigen, Toxicity, Knob, GenScript Biotech, Epitope, Infection, Therapy, Cancer, Monoclonal antibody, Autoimmunity, Coagulopathy, Ligand, Vaccine

TORONTO, Nov. 22, 2023 /PRNewswire-PRWeb/ -- Discover this groundbreaking webinar delving into the strategic approaches of bispecific antibody (BsAb) design, production and purification. BsAbs have become increasingly of interest by enabling new therapeutic applications for a variety of indications, including cancer, chronic inflammatory diseases, autoimmunity, neurodegeneration, bleeding disorders and infections. Currently, there are 12 bispecific antibodies approved worldwide.

Key Points: 
  • Attendees will learn the key considerations of bispecific antibody structural design and analysis of general design strategies.
  • The featured speaker will discuss production strategies and by-product purification plans for bispecific antibodies with different structures.
  • TORONTO, Nov. 22, 2023 /PRNewswire-PRWeb/ -- Discover this groundbreaking webinar delving into the strategic approaches of bispecific antibody (BsAb) design, production and purification.
  • Join this webinar to gain insights into the diverse applications, design considerations and production strategies of bispecific antibodies.

GenScript ProBio Partners With NuclixBio to Pave the Way for South Korea’s First Large-scale Production Process for “Circular RNA Therapeutics”

Retrieved on: 
Thursday, November 9, 2023
FDA, Clinical Trials, Stem Cells, Cardiology, Biotechnology, Alternative Medicine, Health, Pharmaceutical, Oncology, Attention, Therapy, RNA, CMC, CDMO, Internal ribosome entry site, CGT, Cancer, GenScript Biotech, Partnership, Messenger, GMP, IRES, Vaccine

GenScript ProBio, a global multimodality CDMO and NuclixBio, a company developing treatments based on circular RNA, announced on 9th Nov that they have entered into a strategic business agreement to develop the first circular RNA-based anticancer drug in South Korea.

Key Points: 
  • GenScript ProBio, a global multimodality CDMO and NuclixBio, a company developing treatments based on circular RNA, announced on 9th Nov that they have entered into a strategic business agreement to develop the first circular RNA-based anticancer drug in South Korea.
  • With this strategic partnership, both companies will establish the first large-scale production process for circular RNA therapeutics in South Korea from preclinical to clinical stages (with GMP production).
  • This also serves as a cornerstone for NuclixBio's of its circular RNA-based immune cancer treatment to enter full-scale clinical trials.
  • Not only preventive vaccines but also cancer vaccines, immune anticancer drugs, CAR-T, and other areas are seeing mRNA therapy development.

North America Leads the Way: The Regional Powerhouse in the Global Antibody Discovery Services and Platforms Market - ResearchAndMarkets.com

Retrieved on: 
Tuesday, October 24, 2023
Health, General Health, Research, Pharmaceutical, Science, Biotechnology, Type, Antibody Solutions, Therapy, Prevalence, Conditional sentence, ChromeOS, Engineering, Drug development, Growth, GenScript Biotech, Antibody, Platform, USD, Infection, Cancer, Investment, Compound annual growth rate, Twist Bioscience, Nature, Vaccine, Fine chemical, Pharmaceutical industry

Due to the complexities associated with discovering such antibodies, many firms are licensing and utilizing specialized antibody discovery platforms and technologies, driving the growth of the antibody discovery services and platforms market.

Key Points: 
  • Due to the complexities associated with discovering such antibodies, many firms are licensing and utilizing specialized antibody discovery platforms and technologies, driving the growth of the antibody discovery services and platforms market.
  • The global market size for antibody discovery services and platforms is projected to grow at an annualized CAGR of 11.0% during the forecast period.
  • Key players in the antibody discovery services and platforms market include Ablexis, Antibody Solutions, ChemPartner, GenScript, Genmab, Harbour BioMed, ImmunoPrecise, Mabsilico, and more.
  • In March 2023, Twist Bioscience announced the launch of its antibody discovery services under the Twist Biopharma Solutions subsidiary after acquiring Abveris, an antibody discovery CRO, in 2022.

North America Leads the Way in the Global DNA Encoded Library Market, Capturing Over 70% of Market Share by 2035 - ResearchAndMarkets.com

Retrieved on: 
Monday, October 23, 2023
Research, Technology, Neurology, Genetics, Biotechnology, Pharmaceutical, Health, Science, Oncology, Artificial Intelligence, Bristol Myers Squibb, AstraZeneca, Patent, Region, Janssen, Intellectual property, Jaden Philogene, Intellectual, DNA, Drug development, Artificial intelligence, Wuxi, Novartis, Machine learning, DNA-encoded chemical library, DEL, GenScript Biotech, Amgen, Drug discovery, GSK, Chem, DSM-IV codes, Services marketing, USD, Roche, Sanofi, Library, Therapy, Fine chemical, Pharmaceutical industry, Medical device, Computer data storage, Pfizer, Florence Provendier, Dels

With robust innovation and substantial financial support from investors, the DNA encoded library market is poised for remarkable expansion.

Key Points: 
  • With robust innovation and substantial financial support from investors, the DNA encoded library market is poised for remarkable expansion.
  • Market Analysis and Regional Dominance:
    The global DNA encoded library market is estimated to reach USD 840 million in 2023.
  • North America is expected to hold the largest market share, with more than 70% of the market captured by players based in North America and Europe by 2035.
  • Leading DNA Encoded Library Companies:
    Key players in the DNA encoded library market include BOC Sciences, DyNAbind, Edelris, GenScript, HitGen, NovAliX, PROVendis, SpiroChem, Vipergen, WuXi AppTec, and X-Chem.